NextCure Analyst Ratings
NextCure Analyst Ratings
While ratings are subjective and will change, the latest NextCure (NXTC) rating was a initiated with a price target of $0.00 to $7.00. The current price NextCure (NXTC) is trading at is $1.70, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 311.76% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 08/04/2023 | 252.94% | Needham | → $6 | Reiterates | Buy → Buy |
| 05/05/2023 | 252.94% | Needham | → $6 | Reiterates | → Buy |
| 03/03/2023 | 252.94% | Needham | → $6 | Reiterates | → Buy |
| 11/04/2022 | — | Ladenburg Thalmann | Downgrades | Buy → Neutral | |
| 11/04/2022 | 252.94% | Needham | $12 → $6 | Maintains | Buy |
| 11/04/2022 | 252.94% | Piper Sandler | $13 → $6 | Maintains | Overweight |
| 08/23/2022 | 782.35% | Truist Securities | $19 → $15 | Maintains | Buy |
| 05/23/2022 | 664.71% | Piper Sandler | $21 → $13 | Maintains | Overweight |
| 03/01/2022 | 841.18% | Ladenburg Thalmann | → $16 | Initiates Coverage On | → Buy |
| 11/05/2021 | 723.53% | Needham | $30 → $14 | Maintains | Buy |
| 03/05/2021 | 1017.65% | Truist Securities | $13 → $19 | Upgrades | Hold → Buy |
| 01/15/2021 | 488.24% | B of A Securities | $13 → $10 | Downgrades | Neutral → Underperform |
| 07/16/2020 | 900% | Benchmark | → $17 | Upgrades | Hold → Buy |
| 07/14/2020 | 1488.24% | BTIG | $61 → $27 | Maintains | Buy |
| 07/13/2020 | 664.71% | SunTrust Robinson Humphrey | $78 → $13 | Downgrades | Buy → Hold |
| 06/01/2020 | — | Benchmark | Downgrades | Buy → Hold | |
| 05/08/2020 | 3076.47% | Morgan Stanley | $58 → $54 | Maintains | Overweight |
| 04/15/2020 | 3311.76% | Morgan Stanley | $55 → $58 | Maintains | Overweight |
| 03/02/2020 | 4605.88% | Roth Capital | → $80 | Initiates Coverage On | → Buy |
| 01/13/2020 | 4488.24% | SunTrust Robinson Humphrey | → $78 | Initiates Coverage On | → Buy |
| 12/17/2019 | 3135.29% | Morgan Stanley | $52 → $55 | Maintains | Overweight |
| 11/26/2019 | 3488.24% | BTIG | → $61 | Initiates Coverage On | → Buy |
| 11/13/2019 | 2958.82% | Morgan Stanley | $33 → $52 | Maintains | Overweight |
| 11/12/2019 | 5135.29% | B of A Securities | $92 → $89 | Reiterates | → Buy |
| 09/09/2019 | 2488.24% | B of A Securities | $27 → $44 | Reiterates | → Buy |
| 09/05/2019 | 3076.47% | Piper Sandler | $26 → $54 | Maintains | Overweight |
| 08/13/2019 | 1841.18% | Morgan Stanley | $25 → $33 | Maintains | Overweight |
| 07/09/2019 | — | B of A Securities | Initiates Coverage On | → Buy | |
| 06/03/2019 | 1370.59% | Morgan Stanley | → $25 | Initiates Coverage On | → Overweight |
| 06/03/2019 | 1429.41% | Piper Sandler | → $26 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023/08/08 | 311.76% | HC Wainwright公司 | →$7 | 開始承保 | →購買 |
| 08/04/2023 | 252.94% | 李約瑟 | →$6 | 重申 | 購買→購買 |
| 05/05/2023 | 252.94% | 李約瑟 | →$6 | 重申 | →購買 |
| 03/03/2023 | 252.94% | 李約瑟 | →$6 | 重申 | →購買 |
| 11/04/2022 | - | 拉登堡·塔爾曼 | 評級下調 | 購買→中性 | |
| 11/04/2022 | 252.94% | 李約瑟 | $12→$6 | 維護 | 買 |
| 11/04/2022 | 252.94% | 派珀·桑德勒 | $13→$6 | 維護 | 超重 |
| 2022年08月23日 | 782.35% | Truist證券 | $19→$15 | 維護 | 買 |
| 2022年05月23日 | 664.71% | 派珀·桑德勒 | $21→$13 | 維護 | 超重 |
| 03/01/2022 | 841.18% | 拉登堡·塔爾曼 | →$16 | 開始承保 | →購買 |
| 2021年11月05日 | 723.53% | 李約瑟 | $30→$14 | 維護 | 買 |
| 03/05/2021 | 1017.65% | Truist證券 | $13→$19 | 升級 | 持有→購買 |
| 2021/01/15 | 488.24% | B of A證券 | $13→$10 | 評級下調 | 中性→表現不佳 |
| 07/16/2020 | 900% | 基準 | →$17 | 升級 | 持有→購買 |
| 07/14/2020 | 1488.24% | BTIG | $61→$27 | 維護 | 買 |
| 07/13/2020 | 664.71% | SunTrust Robinson Humphrey | $78→$13 | 評級下調 | 購買→Hold |
| 06/01/2020 | - | 基準 | 評級下調 | 購買→Hold | |
| 05/08/2020 | 3076.47% | 摩根士丹利 | $58→$54 | 維護 | 超重 |
| 04/15/2020 | 3311.76% | 摩根士丹利 | $55→$58 | 維護 | 超重 |
| 03/02/2020 | 4605.88% | 羅斯資本 | →$80 | 開始承保 | →購買 |
| 2020/01/13 | 4488.24% | SunTrust Robinson Humphrey | →$78 | 開始承保 | →購買 |
| 2019年12月17日 | 3135.29% | 摩根士丹利 | $52→$55 | 維護 | 超重 |
| 2019年11月26日 | 3488.24% | BTIG | →$61 | 開始承保 | →購買 |
| 2019年11月13日 | 2958.82% | 摩根士丹利 | $33→$52 | 維護 | 超重 |
| 2019年11月12日 | 5135.29% | B of A證券 | $92→$89 | 重申 | →購買 |
| 2019年09月09日 | 2488.24% | B of A證券 | $27→$44 | 重申 | →購買 |
| 2019年05月09日 | 3076.47% | 派珀·桑德勒 | $26→$54 | 維護 | 超重 |
| 2019年08月13日 | 1841.18% | 摩根士丹利 | $25→$33 | 維護 | 超重 |
| 2019年07月09日 | - | B of A證券 | 開始承保 | →購買 | |
| 2019年03月06日 | 1370.59% | 摩根士丹利 | →$25 | 開始承保 | →超重 |
| 2019年03月06日 | 1429.41% | 派珀·桑德勒 | →$26 | 開始承保 | →超重 |
What is the target price for NextCure (NXTC)?
NextCure的目標價是多少？
The latest price target for NextCure (NASDAQ: NXTC) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $7.00 expecting NXTC to rise to within 12 months (a possible 311.76% upside). 8 analyst firms have reported ratings in the last year.
HC Wainwright&Co.於2023年8月8日報道了NextCure(納斯達克代碼：NXTC)的最新目標價。這家分析公司將目標價定為7美元，預計NXTC將在12個月內上漲至(可能上漲311.76%)。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for NextCure (NXTC)?
分析師對NextCure的最新評級是多少？
The latest analyst rating for NextCure (NASDAQ: NXTC) was provided by HC Wainwright & Co., and NextCure initiated their buy rating.
納斯達克(代碼：NXTC)的最新分析師評級由HC Wainwright&Co.提供，NextCure啟動了他們的買入評級。
When is the next analyst rating going to be posted or updated for NextCure (NXTC)?
NextCure的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NextCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NextCure was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與NextCure的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。NextCure的上一次評級是在2023年8月8日提交的，所以你應該預計下一次評級將在2024年8月8日左右提供。
Is the Analyst Rating NextCure (NXTC) correct?
分析師對NextCure的評級正確嗎？
While ratings are subjective and will change, the latest NextCure (NXTC) rating was a initiated with a price target of $0.00 to $7.00. The current price NextCure (NXTC) is trading at is $1.70, which is within the analyst's predicted range.
雖然評級是主觀的，而且會發生變化，但最新的NextCure(NXTC)評級是以0.00美元至7.00美元的目標價啟動的。目前，NextCure的交易價格為1.70美元，在分析師的預測範圍內。